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Breast carcinoma (BC) has been extensively profiled
by high-throughput technologies for over a decade,
and broadly speaking, these studies can be grouped
into those that seek to identify patient subtypes
(studies of heterogeneity) or those that seek to iden-
tify gene signatures with prognostic or predictive
capacity. The sheer number of reported signatures
has led to speculation that everything is prognostic
in BC. Here, we show that this ubiquity is an appari-
tion caused by a poor understanding of the interrelat-
edness between subtype and the molecular determi-
nants of prognosis. Our approach constructively
shows how to avoid confounding due to a patient’s
subtype, clinicopathological profile, or treatment
profile. The approach identifies patients who are pre-
dicted to have good outcome at time of diagnosis by
all available clinical and molecular markers but who
experience a distantmetastasis within 5 years. These
inherently difficult patients (7% of BC) are priori-
tized for investigations of intratumoral heterogeneity.
INTRODUCTION
There has been a sustained effort to identify markers of prog-
nosis in women diagnosed with invasive breast cancer (IBC), a
highly prevalent disease that accounts for 14% of all cancer
deaths in women (Jemal et al., 2011). The estimation of prog-
nosis at time of diagnosis relies primarily upon clinicopatholog-
ical parameters such as tumor size, histological grade, stage,
lymph node (LN) infiltrate, and molecular properties includingexpression of the estrogen receptor (ER), progesterone receptor
(PR), and the human epidermal growth factor receptor 2 (HER2)
(Reis-Filho and Pusztai, 2011). Prognostic insight can in turn
provide predictive insight with respect to patient benefit from
chemo-, endocrine, and targeted therapies.
The paradigm shift promised by technologies that measure
expression of genomic features of IBC in a massively parallel
fashion has inarguably occurred but is tempered by the fact
that few prognostic gene signatures have found clinical use
(Hornberger et al., 2012). The primary contribution of breast
cancer genomics to date has been a deeper appreciation of
IBC heterogeneity (Weigelt et al., 2010). Although the four clinical
subtypes defined by ER and HER2 status have long been recog-
nized as distinct forms of the disease, early genomic studies
underscored their vast differences at the molecular level (Gruv-
berger et al., 2001; Perou et al., 2000) and stimulated work to
identify other markers that capture proliferation, progenitor cell
properties, androgen-receptor-related signaling, and other biol-
ogies (Desmedt et al., 2008; Guedj et al., 2012; Rakha et al.,
2010). Moreover, unbiased bioinformatic analyses of profiles
generated the so-called intrinsic subtyping scheme, consisting
of two subtypes enriched for ER+ tumors (luminal A, B), a
HER2+-enriched subtype (her2-enriched), a ER/HER2-en-
riched subtype (basal-like), and a so-called normal-like subtype
(Perou et al., 2000; Sørlie et al., 2001). The intrinsic subtyping
scheme has been refined (Parker et al., 2009) and extended to
include the claudin-low class of tumors that display a high fre-
quency of metaplastic and medullary differentiation (Prat et al.,
2010). Other genomics-based subtyping schemes have been
proposed, including the Cartes d’identite´ des tumeurs (CIT)
scheme (Guedj et al., 2012), a ‘‘triple negative’’ specific scheme
(Lehmann et al., 2011), a scheme based on joint DNA and RNA
copy number (Curtis et al., 2012), and others (Haibe-Kains
et al., 2012; Jo¨nsson et al., 2010; Wirapati et al., 2008).Cell Reports 9, 129–142, October 9, 2014 ª2014 The Authors 129
Figure 1. Characteristics of the ExpC and Subtyping Schemes
(A) The compendium of IBC gene expression profiles by intrinsic and clinical
schemes. Total number of subjects with observed good (superscript) and poor
(subscript) outcome, respectively.
(B) Kaplan-Meier plots of observed patient outcome defined as distant
metastasis-free survival across the ExpC in both the clinical and intrinsic
schemes.
See also Figures S1 and S2.In parallel with, but largely disjoint from, this work, many
(>100) gene signatures have been reported to have prognostic
capacity in IBC. The signatures were typically derived either
by manual curation of specific molecular processes (e.g., anti-
gen presentation and processing [APP] pathway), from experi-
mental perturbations in cell lines and transgenic mouse models
of the disease (e.g., Ursini-Siegel et al., 2010), or directly from
gene expression profiles of IBC samples by contrasting
observed good and poor outcome patients (van ’t Veer et al.,
2002). A classification of good prognosis by a signature sug-
gests that an individual will respond positively to standard of
care for their tumor type, whereas a prediction of poor prognosis
suggests the need for an alternative regimen. Clinical utility for a
few signatures has been established and translated to the clinic
(Hornberger et al., 2012), including, for example, OncotypeDX,
which assists in determining which ER+/LN patients may
benefit from additional adjuvant chemotherapy (Paik et al.,
2004).
Themarginal overlap and the differences in the underlying bio-
logical processes polled by these signatures have generated
criticisms regarding experimental design and lack of standard-
ized bioinformatics techniques (Ioannidis et al., 2009), leading
to speculation that almost all genes and processes are prog-130 Cell Reports 9, 129–142, October 9, 2014 ª2014 The Authorsnostic in IBC (Venet et al., 2011). However, the root cause of
the myriad of dissimilar signatures may be primarily due to
deep, structural interdependencies between a patient’s clinico-
pathological profile, tumor subtype, and prognosis (Iwamoto
and Pusztai, 2010). Here, we clarify the nature and ubiquity of
this poorly understood confounding.
The prognostic predictions made by published gene signa-
tures are compared enmasse patient by patient, in order to iden-
tify if andwhere additional progress is possible. Using essentially
all available data, this investigation establishes that there is large
confounding in existing signatures between clinicopathological
variables, subtype, and clinical outcome. A de novo subtyping
scheme is presented that ablates the majority of these effects.
The resultant scheme highlights approximately 20% of patients
whose prognosis appears inherently difficult to predict at time
of diagnosis.
RESULTS
A Comprehensive Examination of Prognosis in Breast
Cancer
Publicly available gene expression data sets for IBC were evalu-
ated according to technical quality, clinical attributes, treatment
regimen, data set size, and patient outcome (Supplemental
Experimental Procedures, 2.1). Data sets deemed sufficient
were harmonized as much as possible (Supplemental Experi-
mental Procedures, 2.1.1) to measure patient outcome as
event-free survival at 5 years (good outcome) versus the exis-
tence of distant metastases within the same time interval (poor
outcome). The resultant compendium, referred to as the ExpC,
contains approximately 5,000 patients from over 11 data sets
using seven microarray and RNA-sequencing (RNA-seq) plat-
forms (Table S1), including our de novo effort (McGill Genome
Quebec [MGGQ] n = 314, GSE58644).
Samples of ExpC were labeled according to five subtyping
schemes, where possible (Figure 1A; Table S7). ER and HER2
status were used to determine the so-called clinical subtypes
(ER+/HER2+, ER+/HER2, ER/HER2+, and ER/HER2).
The PAM50 gene set (Parker et al., 2009) was used for the
intrinsic subtypes of luminal A (lumA), luminal B (lumB), normal-
like (normL), basal-like (basalL), and her2-enriched (her2E).
Patients were also labeled according to the IntClust (Curtis
et al., 2012), CIT (Guedj et al., 2012), and triple-negative breast
cancer (TNBC) (Lehmann et al., 2011) schemes (Tables S1 and
S7). Although there are enrichments between subtypes of
different schemes, all five are distinct (Table S2; see also Tables
S4 and S5 and Figure S1). As expected, the vastmajority (96.5%)
of luminals (lumA and lumB) is ER+; however, over 25%of basalL
and 50% of her2E patients are ER+ (Figure 1A).
We collected gene signatures from the literature reported to
have prognostic capacity in IBC (n = 106; Table S3). Together,
the signatures use one-third (6.4K) of all human genes with
few appearing in multiple signatures (Table S9). Not sur-
prisingly then, these signatures are enriched for a wide range of
biological processes (Table S3). Using a standardized technique
with each prognostic signature, a naive Bayes’ classifier was
trained for each patient subtype within each subtyping scheme
when there were a sufficient number of good- and poor-outcome
individuals (Supplemental Experimental Procedures, 2.6). This
procedure was carried out systematically, and each signature
was evaluated in all subtype stratifications irrespective of the
subtype in which the signature was originally derived. We also
developed de novo classifiers using the same methodology for
training (Figure S2E; Supplemental Experimental Procedures,
2.7). The performance of both the de novo and literature-derived
classifiers was thoroughly investigated (Figures S2F–S2I). This
signature collection is referred to as SigC (n = 122). All analyses
are available at http://www.bci.mcgill.ca/bresect.
Prediction of Outcome Is Confounded in Pan-IBC
Analysis
When patient subtype is not considered in the training and appli-
cation of classifiers, almost every signature in SigC appears
capable of predicting patient outcome (89% with log-rank test
p < 0.05; ‘‘unstratified’’ in Figure 2A). This suggests that an
extremely broad range of biological processes represented
by signatures in SigC including proliferation (Vanvliet-2008),
microenvironmental factors (Finak-2008), and immunological re-
sponses (Rody-2009) all have prognostic capacity, an observa-
tion consistent with previous reports (Venet et al., 2011; Weigelt
et al., 2010).
To investigate this apparent ubiquitous prognostic signal, we
plotted the predictions of individual SigC classifiers across all
patients stratified by outcome (Figure 3). The classifiers are
ordered from top to bottom by decreasing performance in both
good and poor outcome (Supplemental Experimental Proce-
dures, 2.6.1). Only 56% of SigC signatures perform better
than random signatures built by choosing 25 arbitrary genes
(Figure 3F). Those classifiers that did not perform better than
random (Figure 3G) tend to systematically predict all patients
as good outcome, likely because the majority (79%) of patients
with IBC have good outcome. Such classifiers offer neither
clinical utility nor insight into the molecular mechanisms of the
disease.
The classifiers that outperform 99% of random gene signa-
tures exhibited a high degree of agreement in their predictions.
That is, either all signatures predict the patient to be good
outcome (Figures 3B and 3E) or poor outcome (Figures 3C and
3D). Figures 3B and 3C then represent patients that are easy
to predict correctly, whereas Figures 3D and 3E represent pa-
tients that appear inherently difficult to predict.
We asked if the surprisingly concordant incorrect predictions
for the patients in Figures 3D and 3E could be due to the fact
that the classifiers systematically confuse patient outcome with
intrinsic subtype or other clinicopathological variables. To do
this, a de novo statistical method entitled the Systematic
MisPrediction (SMP) test was developed that identifies when
predictions of outcome made by the classifiers en masse are
highly associated with a variable of interest (e.g., ER status,
treatment) within both the good- and poor-outcome subcohorts
(Supplemental Experimental Procedures, 2.6.3). In essence, sig-
nificance for the SMP test suggests that the classifiers have
learnt to predict the variable of interest rather than patient prog-
nosis per se.
For example, across all IBC samples, the SMP test finds that
ER status is highly significant (p < 0.001; Table 1): nearly allER+ patients are classified as good outcome, and nearly all
ER are assigned poor outcome. This represents systematic
misprediction, since there are a significant number of both
poor-outcome ER+ patients and good-outcome ER patients;
these patients are almost never predicted as such by the SigC
classifiers. Intrinsic subtypes were similarly found associated
with systematic misprediction of outcome; patients were pre-
dicted as good outcome if and only if their subtype was lumA,
lumB, or normL (Table 1; Figure 3H). In summary, although the
SigC classifiers were trained to predict outcome, they have
instead learnt (clinical or intrinsic) subtype.
Prediction of Outcome Is Confounded in ER and HER2
Defined Cohorts
We asked if prediction of outcome within cohorts restricted to
only ER+ tumors would ablate confounding. Here, 77% of the
SigC classifiers still remain significant under survival analysis
(log rank, p < 0.05; Figure 2A), and the SMP test establishes
that the classifiers consistently assign prognosis according to
intrinsic subtype: lumA and normL patients as good outcome,
and her2E and basalL patients as poor outcome (p < 0.001 for
each intrinsic subtype; Table 1; Figure S3A). Similar problems
were identified for ER, HER2, and HER2+ cohorts (Table 1;
Figures S3B and S3C). In fact, instead of prognosis, the classi-
fiers built for ER-defined subtypes tend to learn HER2 status
and HER2 cohorts learn ER status. The differential in rates of
poor outcome between ER+ and ER cohorts explains their
apparent prognostic capacity (similarly for HER2), suggesting
that the prognostic classifiers have no power to predict outcome
above and beyond the information implicit in the patient’s
subtype.
Limitations of the Clinical and Intrinsic Schemes
We next built SigC classifiers for each subtype of the clinical
scheme. No signature had significant prognostic capacity in all
four cohorts (Figure 2A). The ER+/HER2 cohort contained the
greatest degree of systematic misprediction where patients
were still predicted based on their intrinsic subtype (Table 1; Fig-
ure S3C). The ER/HER2 cohort contains a high number of
claudin-low (CL) patients (p < 0.0001; Table S2) with evidence
of systematic misprediction of CL patients as good prognosis
(SMP test, p < 0.0001; Table 1). We investigated the refinement
of the ER/HER2 subtype into CL and non-CL cohorts for
prognostic prediction but identified only 12 weakly differentially
expressed genes (linear models for microarray data [limma],
false discovery rate < 0.5; Table S10).
With respect to the intrinsic subtypes (Figure 2B), patients with
high-grade tumors were systematically mispredicted as poor
outcome within the lumB subtype (SMP test, p < 0.01; Table 1;
Figure S3D). Since high-grade tumors often receive chemo-
therapy, it is not surprising that patients who received chemo-
therapy were also systematically mispredicted as poor outcome
(p < 0.01). As per the ER/HER2 clinical subtype, basalL was
confounded by CL status with good prognosis assigned to CL
individuals (SMP test, p < 0.01; Figure S3D).
The SMP test did not identify significant confounding by ER or
HER2 status for the normL, basalL, or her2E subtypes, suggest-
ing that these subtypes represent a sufficiently homogeneousCell Reports 9, 129–142, October 9, 2014 ª2014 The Authors 131
Figure 2. Subtype-Specific Performance of Prog-
nostic Classifiers
Colors are proportional to the rank of the classifier within the
specific patient cohort, with red representing the highest-
performing classifiers relative to the remaining SigC
members. Ticks represent the level of significance of the
classifier (log-rank test, p < 0.05, 0.01, 0.001, respectively).
Bottom row contains percentage of SigC significant at p <
0.05. Major signatures of interest have been highlighted.
See also Figure S2.
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Figure 3. Patient-Signature Heatmap of Classifiers in Unstratified Analysis of IBC
Blue and red shaded columns correspond to good- and poor-outcome patients, respectively. The classifiers (rows) from SigC are ordered by their ability to
predict patient outcome. Asterisks correspond to significance by survival analysis (log-rank test). Dark and light shades correspond to correct and incorrect
predictions, respectively. Patients (columns) are ordered by the degree of agreement of predictions across all members of SigC across good and bad outcome.
(A) Difficulty score of predicting outcome.
(B and C) A subset of patients that almost every classifier predicts correctly.
(D and E) Patients mispredicted by almost every classifier.
(F) The percentage of trials (n = 100K) whereby the specific classifier (row) outperformed a classifier built from a random set of k = 25 genes.
(G) The box shades the subset of classifiers from SigC that does not outperform classifiers built from a random set of k = 25 genes over 99% of the trials.
(H) Clinicopathological, treatment, and subtype attributes per patient. A red tick in ‘‘Outcome (5 yrs)’’ refers to an observed distant metastasis within 5 years.
‘‘Outcome’’ does not place a restriction on length of follow-up. Color-coding for PAM50 and IntClust follows original publications. Color-coding for data sets is
given in Table S1.
See also Figure S3.
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Table 1. Table of Associations from the Systematic MisPrediction Test
IHC Treatment Patient Tumor PAM50 Claudin-Low
ER HER2 Chemotherapy Tamoxifen Age LN Size Stage Grade lumA lumB normL her2E basalL CL
Unstratified ++++   ++++ ++++  ++++ ++++ ++++  
ER+ NA    ++++ ++++  
ER NA  NA  ++ ++++
HER2+ ++ NA ++
HER2 ++++ NA  ++++ ++++  ++++ ++++ 
ER+/HER2+ NA NA NA NA
ER+/HER2 NA NA   ++++ ++++  
lumA NA NA NA NA NA NA
lumB  NA NA NA NA NA
normL NA NA NA NA NA
her2E NA NA NA NA NA
basalL NA NA NA NA NA ++
ER/her2E NA NA NA NA NA NA
ER/basalL NA NA NA NA NA NA ++
ER+/lumA NA NA NA NA NA NA
ER+/lumB  NA NA NA NA NA
ER+/normL NA NA NA NA NA NA NA
ER+/her2E NA NA NA NA NA NA
ER+/basalL NA NA NA NA NA NA NA
ER/HER2+ NA NA NA NA
ER/HER2- NA NA NA NA ++++
Each entry represents the extent to which consistent misclassification with a specific subtype (row) is associated with a specific clinicopathological or
patient attribute. ‘‘+’’ indicates that patients positive for that attribute are systematically assigned good prognosis, and ‘‘’’ indicates the reverse. The
number of ticks (two, three, or four) corresponds to p values < 0.01, 0.001, and 0.0001, respectively. NA indicates insufficient data.group of patients suitable for prognostic studies. The homoge-
neity suggests that a biological process that has prognostic
capacity in an ER+/her2E tumor will also have capacity in an
ER/her2E tumor, and vice versa. However, a comparison of
the SigC classifiers between the her2E, ER+/her2E, and
ER/her2E cohorts shows a marked difference (Figure 2C; Fig-
ure S4A). The most significant classifiers for ER+/her2E poll
biological processes shown previously to be prognostic in ER+
tumors (e.g., Chanrion-2008). In contrast, several classifiers
are only prognostic in ER/her2E including metastasis to bone
(Smid-2006) and lung (Minn-2005) signatures and diverse
immune-related signals (Beck-2009, Rody-2009, Tosolini-2001,
and Ursini-Siegel-2010). Lastly, the ER+ and ER subcohorts
of her2E have distinct survival characteristics, suggesting that
her2E is a very heterogeneous subtype (Figure S2B; log-rank
test, p < 0.0001; Cox proportional hazards: 1.86, 95% confi-
dence interval: [1.34, 2.59]).
Similarly for the basalL related comparisons (Figure S4B), rela-
tively few (22%) SigC classifiers are significant for ER+/basalL
tumors compared to ER/basalL (Figure 2D). Although ER+
and ER basalL tumors displayed similar survival characteristics
(Figure S2C), ER+/basalL were less likely to have received
chemotherapy (Table S2).
Together, these differences suggest that joint clinical and
intrinsic subtyping may be necessary to move beyond the
strong, dominant ER- and HER2-related signals found in IBC.134 Cell Reports 9, 129–142, October 9, 2014 ª2014 The AuthorsIdentification of a De Novo Hybrid Subtyping Scheme
We computationally searched across all possible combi-
nations of the clinical and intrinsic subtyping schemes for a
hybrid approach maximizing prognostic capacity while mini-
mizing systematic misprediction. The most complicated hybrid
scheme would partition tumors into 20 subtypes: 2 (ER±) 3 2
(HER2±) 3 5 (intrinsic subtypes). A single gene expression-
based classifier would be created for each subtype (Supple-
mental Experimental Procedures, 2.7; Figures S2E and S2F;
Table S7). For example, an ER+, HER2+, and basalL tumor
would be evaluated with a classifier learnt previously in a
training set specific to this cohort.
This search identified a scheme that partitions IBC into seven
hybrid subtypes (Figure 4A). For ER+ tumors, intrinsic subtyping
is used for further refinement. For ER tumors, the search rec-
ommends the use of only HER2 status. Figure 5 depicts the per-
formance of the SigC classifiers across the hybrid subtypes
(Ward’smethod, Euclidean distance) with Figures 5A–5C depict-
ing performance, overlap between signatures, and the MSigDB
molecular processes enriched in these gene sets (Subramanian
et al., 2005; Supplemental Experimental Procedures, 2.4).
Although none of the SigC classifiers were significant across
all hybrid subtypes, the most universal (area labeled ‘‘Immune
SigC’’) or significant (‘‘Top’’) classifiers were mainly immune
related: Ursini-Siegel-2010, Finak-2008, and Rody-2009 signa-
tures (Figure 5A).
Figure 4. The Hybrid Subtyping Scheme
(A) A decision tree where the root corresponds to all patients. ER+ samples move left in the tree. The row labeled ‘‘vs. Unstratified’’ is a comparison of the
predictions made by a classifier trained in unstratified analysis versus the classifier trained in an ER+-restricted cohort. Green entries correspond to samples
where the ER+-restricted classifier is correct but the parental classifier is incorrect (improvements due to additional stratification). Brown corresponds to incorrect
predictions by the ER+ classifier but correct predictions by the unstratified classifier (deteriorations). The row labeled ‘‘Clinical’’ at each node of the tree compares
classifiers built with the hybrid scheme versus classifiers built using the clinical scheme (similarly for row ‘‘Intrinsic’’). For instance, for an ER+/HER2/basalL
sample, the row labeled ‘‘vs Intrinsic’’ compares the prediction made by a ER+/basalL classifier with a basalL classifier, while the row labeled ‘‘vs Clinical’’
compares the predictions made by a ER+/basalL classifier with a ER+/HER2 classifier.
(B) Patient-signature heatmap for each hybrid subtype as per Figure 2. Vertical black lines delimit the inherently easy and difficult cases within both good-
outcome (blue) and poor-outcome (red) portions.
See also Figure S4.The coclustering of ER+/lumA and ER+/lumB in Figure 5A sug-
gest that roughly the same signatures (labeled ‘‘Sub-ER+’’ and
‘‘ER+ SigC’’) have prognostic capacity in both cohorts, in turn
suggesting that both cohorts share the same prognostic biolog-
ical processesprimarily related toproliferation andcell cycle (Fig-
ures 5B and 5C, pink region). However, some immune-related
signatures appear to have more prognostic capacity in ER+/
lumB than inER+/lumA (e.g., Ursini-Siegel-2010 andBeck-2009).
The hybrid scheme separates classification of ER+/her2E
tumors from ER/HER2+ tumors. Consistent with this is the
observation that very few SigC signatures are significant in
both cohorts (e.g., immune related signatures Ascierto-2012,
APP, and a chromosomal instability signature, Carter-2006).
The scheme recommends separate classifiers for the ER+/
normL cohort, whereas ER/normL tumors should be classified
using ER/HER2 (Figure 4A). The ER+/normL subtype is an
outgroup within the ER+ subtree containing lumA, lumB, and
her2E (Figure 5A), and some of the most prognostic signatures
for this subtype are shared with ER cohorts (e.g., Yau-2010
and Hallett-2012).Finally, we observe that the ER+/basalL subtype is most
similar to ER related cohorts. However, some ER+/basalL sig-
natures do remain significant within the ER+/luminal subtypes
(e.g., Saal-2007) but are not significant in the ER/basalL sub-
type, suggesting that ER+ and ER basalL tumors are signifi-
cantly different from a prognostic perspective (Figure S4B).
The Hybrid Scheme versus Alternatives
The hybrid scheme was then compared against alternative sub-
typing schemes including IntClusters (IC), CIT, and the TNBC
subtypes. For each hybrid subtype, we asked (1) if it contains a
surprising number of patients from a subtype of an alternative
scheme (Table S2) and (2) if the SMP test identified a subtype
from an alternative scheme that confounds prognostic predic-
tions (Table S8).
ER+/lumB contains surprisingly many tumors of subtype IC8
and IC9 (both p < 0.0001; Table S2). The IC9 subtype corre-
sponds to ER+ tumors with 8q cis-acting/20q-amplification
events (Curtis et al., 2012). Within ER+/lumB, they are systemat-
ically mispredicted as poor outcome (p < 0.01). The IC8 tumorsCell Reports 9, 129–142, October 9, 2014 ª2014 The Authors 135
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are characterized by classical 1q gain/16q loss. In ER+/lumB,
these tumors are systematically mispredicted as good outcome
(p < 0.01).
With respect to ER/HER2 tumors, we observed systematic
misprediction of IC4 tumors (characterized by extensive lympho-
cytic infiltration) as good outcome and IC10 tumors (character-
ized as primarily basalL tumors by Curtis et al.) as poor outcome
(both p < 0.0001).
Our attempts to develop prognostic classifiers for refinements
of the hybrid subtypes that include IC subtypes were limited by
the fact that IC subtypes are currently only available within the
Curtis et al. data set (Curtis et al., 2012). Notably, when we
trained prognostic classifiers for each of the 10 IC subtypes
alone, their performance did not achieve statistical significance
in the validation portion of their data set.
There were also surprisingly many CIT-’’lumC’’ tumors within
the ER+/basalL hybrid subtype (Table S2; p < 0.0001) that
were systematically predicted as good outcome (Table S8; p <
0.001). This is surprising, since ‘‘lumC’’ is characterized as a
highly proliferative subtype with relatively poor prognosis (Guedj
et al., 2012). This suggests that the restrictive ER+/basalL sub-
type still contains latent confounding due to the expression of
proliferation genes.
A Trade-Off between Systematic Misprediction and
Performance
The hybrid scheme identifies a partitioning of IBC that reduces as
best possible the systematic misprediction of patient outcome.
Somewhat counterintuitively, however, the ablation of system-
atic misprediction may appear to hinder our ability to predict
survival times. The removal of confounding variables and subse-
quent increased homogeneity of the hybrid subtypes should
allow classification based on actually biological processes that
associate with patient outcome. We plotted the improvements
and deteriorations between the hybrid, clinical and intrinsic
schemes (Figure 4A). Here, each patient is first subtyped by
each of the three schemes, and then outcome is predicted via
a classifier specific for each of the assigned subtypes (Supple-
mental Experimental Procedures, 2.7). All classifiers were
developed with the same methodology. Indeed, the overall per-
formance of the hybrid scheme is only slightly better than previ-
ous subtyping schemes (Figure S2D for survival; +3% product of
accuracy). The performance within the ER+/lumA subtype is
inferior but increases in the ER+/lumB, ER+/basalL, and ER+/
her2E hybrid subtypes.
The Inherent Complexity of Tumors
The performance of the SigC classifiers across the hybrid sub-
types is plotted in Figure 5A (see also Figures S3C–S3E). In every
hybrid subtype, we observe a set of patients who are correctlyFigure 5. The Prognostic Capacity of Each Classifier from SigC across
(A) Colors are proportional to the rank of the signature within the specific patient c
of significance of the classifier in the cohort (log-rank test, 0.05, 0.01, 0.001). Leftm
contains a hierarchical clustering of the hybrid subtypes. Major signatures of inte
(B) Rows correspond to genes that appear as members of at least three SigC sig
(C) Rows correspond to signatures from MSigDB that have surprisingly large ove
molecular function.predicted to have good outcome by almost every SigC classifier
and likewise a set of patients consistently correctly predicted as
bad outcome (Figure 4B). We term these patients ‘‘inherently
easy.’’ Given the diversity of biology that the different classifiers
poll to make predictions, this agreement suggests that many
distinct biological processes expressed in these tumors have
prognostic capacity. In contrast, we also observe patients that
appear to be systematically misclassified by almost every
member of SigC. The outcome of these patients appears to be
‘‘inherently difficult’’ to predict. The black vertical bars delimit
the inherently easy/difficult good/poor outcome patients based
uponour denovo statistic usedquantify thedifficulty of predicting
outcome (Supplemental Experimental Procedures, 2.6.2). The
difficulty score for each patient is a function of how many of the
SigC signatures incorrectly predict its outcome, but weighting
the contribution of each signature by its overall performance.
The existence of inherently easy and difficult patients was also
witnessed in analyses without stratification and with alternative
subtyping schemes; however, these inherent classes were found
to be the result of confounding due to underlying clinicopatho-
logical variables (Table S8). Here with the hybrid scheme,
there is minimal systematic misprediction with known variables,
implying that the inherent easy and difficult classes remain unex-
plained. We verified that the inherent ease and difficulty was not
caused by technical reasons such as the choice of classifier
method; partition of ExpC into training, testing, and validation;
cellularity of samples (Table S6; e.g., fibroblasts); and other vari-
ables (Supplemental Experimental Procedures, 2.14).
The Inherent Complexity of ER/HER2 Tumors Is
Reflected at the DNA Level
To investigate whether the inherent complexity of tumors
observed in RNA profiles was conserved at the DNA level, we
selected three ER/HER2 samples from patients determined
as easy good, difficult good, and difficult poor outcome in the
MGGQ data set. The tumors were subjected to massively paral-
lel exome sequencing (Nextera; Supplemental Experimental
Procedures, 2.8). In total, 232,000,000 read pairs were uniquely
aligned to the human genome (NCBI, hg19) with an average
sequencing depth of 400–600 reads per exonic site. CoNIFER
(Krumm et al., 2012) was used to identify regions of deletions
and amplification in each sample while excluding regions poly-
morphic in normal, healthy samples (Supplemental Experimental
Procedures, 2.8). In total, 118 loci contained 280 distinct genes
with differing copy number in at least one of the three individuals
were identified (Figure 6). A correlation of 0.8 with respect
to the copy number for these loci was observed between
the inherently easy good-outcome and the inherently difficult
poor-outcome individuals (Spearman, p < 1015). In contrast,
no significant correlation was observed between the inherentlythe Hybrid Subtypes
ohort, with red representing the highest performance. Ticks represent the level
ost column is the percentage of SigC significant at p < 0.05. Rightmost column
rest have been highlighted.
natures.
rlap with at signatures in SigC (Fisher’s exact test, p < 0.01). Rows grouped by
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Figure 6. AComparison of Exonic Differences
between Three Samples that Differ in
Outcome and Difficulty of Prediction
Columns correspond to an inherently easy, good-
outcome patient (left); an inherently difficult, poor-
outcome patient (middle); and an inherently easy,
poor-outcome patient (right). Each row represents a
contiguous series of exons that had significantly
different DNA copy number labeled by genes con-
tained in the regions. Yellow represents increased
copy number in comparison to blue (Z transformed).
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easy and difficult poor-outcome samples (Spearman correla-
tions < 0.2, p = 0.06).
DISCUSSION
Subtyping Reshapes the Landscape of Prognosis
Signatures reported to have prognostic capacity in IBC were
systematically compared across a large compendium of expres-
sion profiles. When all IBCs are considered, or when liberal
subtypes defined only by ER or HER2 status are used,most clas-
sifiers had statistically significant ability to predict patient
outcome. This ubiquity, which has been reported previously
(Sotiriou and Pusztai, 2009; Venet et al., 2011; Weigelt et al.,
2010), is difficult to comprehend given the great diversity of bio-
logical processes that are polled by the individual signatures.
Using our de novo SMP test, we are able to explain such
behavior by quantitatively identifying clinicopathological vari-
ables that confuse the prediction of outcome. In unstratified
analysis, the classifiers only predict ER status. Since there are
differential rates of poor outcome between ER+ and ER tumors
(Parl et al., 1984), the classifiers have a prognostic capacity pro-
portional to this differential. For variables such as ER status, the
molecular differences between ER+ and ER subtypes are so
large that almost any gene or gene set is likely to exhibit differen-
tial expression between the subtypes (Gruvberger et al., 2001),
implying the magnitude of the transcriptional fingerprint of ER
is more predominant than signals directly associated with
patient prognosis. The confusion between prognostic and clas-
sification markers explains the apparition that ‘‘almost every-
thing’’ is prognostic in breast cancer.
The Insufficiency of the Clinical Scheme
The clinical subtypes do not remove all systematic misprediction
of prognosis. For example, in the ER+/HER2 cohort, the clas-
sifiers predicted nearly all lumA and normL tumors to have
good outcome, while basalL and her2E were assigned poor
outcome. This is due possibly to the fact that pathologic determi-
nation of ER positivity in the clinic is intentionally permissive
ranging from few (1%) to many (10%) ER+ cells (Iwamoto
et al., 2012), since all such patients may benefit from anties-
trogen therapies (Harbeck and Rody, 2012). In cases where
few ER+ cells are present in the tumor bed, the molecular signal
related to ER may be weak in the expression profile and tools
such as PAM50 for intrinsic subtyping may identify more sub-
stantive her2E or basalL signals, as observed by others (Deyar-
min et al., 2013). The ER+/HER2 cohort is heterogeneous
(Aparicio and Caldas, 2013), and our results establish that this
heterogeneity impairs the prediction of outcome.
The Insufficiency of the Intrinsic Scheme
With respect to the intrinsic scheme, there are notable issues
surrounding the her2E, normL, and basalL subtypes. In all three
cases, these intrinsic subtypes have a significant number of both
ER+ and ER tumors (ER+: her2E 58.7%, basalL 26.3%, normL
79.5%). For her2E, the two ER-defined subcohorts show signif-
icant differences in disease-free survival, and prognosis is pre-
dicted by a distinct set of classifiers. Surprisingly, no signature
was observed to be significant for both ER+ and ER HER2-related cohorts, with few immune-related exceptions that
appear to be prognostic in most subtypes (not necessarily
HER2 related). The paucity of HER2-specific signatures is sur-
prising given that some (e.g., Khoury-2010, Staff-2010, and
Liu-2012) were built explicitly for this purpose. Although HER2
amplification is a good predictive marker for response to anti-
HER2 therapy across all IBCs, these results establish that it
does not function as prognostic marker within the HER2
subcohort.
For basalL, the classifiers most significant for ER+/basalL
differ from those significant for ER/basalL. Several signatures
significant for ER/basalL patients were not significant within
ER+/basalL patients, including several immune-related signa-
tures (Galon-2006 and Rody-2011) and the APP pathway.
The Hybrid Subtyping Scheme
In order to ablate misprediction and confusion, we considered all
possible subtyping schemes that can arise from combining the
clinical and intrinsic subtypes. The focus was placed on these
two schemes since they are the most clinically feasible (Harbeck
et al., 2014). This produced the decision tree of Figure 4A.
For ER tumors, the search identified only HER2 status as sig-
nificant, which is a surprising lack of refinement given the atten-
tion subtyping within ER tumors has received. The ER/lumA
and ER/lumB subtypes studied by Prat et al. (Prat et al.,
2013) were too infrequent in the ExpC (n = 23, one poor outcome;
n = 20, seven poor outcome, respectively) for deeper statistical
evaluation. We compared classifiers for ER/HER2 tumors
with the more restricted cohort of ER/HER2/basalL but failed
to identify a difference in survival characteristics, standard of
care, or significant SigC classifiers, suggesting that basalL is
not a proper subset of ER/HER2 tumors.
ER/HER2/claudin-low (CL) tumors have significantly better
prognosis than non-CL counterparts and were systematically
mispredicted as good outcome by ER/HER2 classifiers. We
were, however, unable to identify markers of prognosis between
good- and poor-outcome ER/HER2/CL patients. Together,
this suggests that although the ER/HER2/CL subtype has
interesting molecular and pathological properties (Prat et al.,
2010), they do not assist in the prediction of outcome. IC4 of
IntClusters is highly enriched in ER/HER2 tumors, and the
patient overlap between IC4 and CL is extremely high, suggest-
ing near equivalence.
The hybrid scheme recommends the partitioning of ER+
tumors by intrinsic subtype. In particular, ER+ and ER HER2+
tumors are segregated for prognostic treatment. The distinctive-
ness of ER+/her2E is in agreement with randomized clinical trials
that have found benefit in dual targeted treatment combining
endocrine and anti-HER2 treatment (Montemurro et al., 2013).
In the ExpC, the ER+/basalL patients appear to have been
treated solely as ER+ tumors receiving tamoxifen but were less
likely to have received chemotherapy in comparison to ER/
basalL, especially for LN+ patients. This is likely due to the fact
that intrinsic subtyping is not clinically available. Although ER+
tumors may be more resistant to chemotherapy than ER
tumors (Rouzier et al., 2005), ER+/basalL cases may represent
candidates that stand to benefit from broader use of chemo-
therapy. Consideration of a novel treatment strategy for theCell Reports 9, 129–142, October 9, 2014 ª2014 The Authors 139
ER+/basalL hybrid subtype may have clinical relevance, since
they have the highest rate of recurrence within ER+ tumors, at
double the frequency of poor-outcome cases as lumB.
The Prognostic Axis across All Signatures
The clustering in Figure 5A highlights the relationships between
the members of the SigC and the hybrid subtypes. At one
end of the axis (‘‘ER-SigC’’), the signatures have prognostic
capacity almost exclusively within ER-related cohorts and
poll aspects of the immune response. At the other end of the
axis (‘‘ER+SigC’’), the signatures have the most capacity in
ER+ tumors and poll processes such as proliferation, cell cycle,
and regulation of transcription. Some ER-related signatures
have some prognostic capacity within ER+ cohorts, including
two of the highest-performing signatures across all hybrid sub-
types (Finak-2008 and Ursini-Siegel-2010). Neither of these sig-
natures was originally learnt in gene expression profiles from
bulk (epithelial enriched) clinical samples of IBC but instead
from stroma-microdissected clinical samples and transgenic
mousemodels of the disease, respectively. Both have significant
adaptive immune and microenvironmental components. This
leads to a hypothesis that gene signatures built in contexts
where ER-related signaling is ablated or irrelevant tend to be
the most universal across IBC.
The Inherent Difficulty of Some Tumors
Although the degree to which a biological process can predict
outcome varies according to subtype, the existence of the inher-
ently difficult and easy classes of tumors (Figure 4B) does sug-
gest that almost every biological process has some degree of
prognostic ability in every subtype. This would suggest that the
molecular profile of, for example, an inherently easy individual
contains a clear and universal signal of prognosis that is
‘‘encoded’’ in almost every biological process, regardless of
tumor grade, stage, LN status, age, subtype, or any other
patient/tumor property. In essence, for good-outcome individ-
uals, standard of care was sufficient for the individual given their
exposures, lifestyle choices, genotypic polymorphisms, tumor
colony structure, and other variables.
For poor-outcome inherently easy individuals, this implies that
at time of diagnosis before treatment the molecular profile con-
tained a ubiquitous signal that the tumor was likely to progress
under standard of care. Factors such as low-penetrant resis-
tance subcolonies and intratumoral complexity do not play
a role.
Almost no genes or pathways are differentially expressed be-
tween inherently difficult, good-outcome and inherently easy,
poor-outcome individuals. There are many possible reasons
why two individuals who have essentially identical transcrip-
tomes may have differing outcome, such as lifestyle, exposures
(Poole et al., 2013), genotypic variation (Landmark-Høyvik et al.,
2013), and other variables largely ignored to date in genomic
studies. It is possible that an epigenetic mark, posttranslational
modification, expressed microRNA, or other genomic features
not measured in transcriptional studies could distinguish these
individuals. However, we comment that such an alternative
mark would have to have had no feedback on transcriptional
levels. For example, the hypothetical epigenetic mark must not140 Cell Reports 9, 129–142, October 9, 2014 ª2014 The Authorshave disrupted the expression of transcripts; otherwise, its
fingerprint would be detected in these studies. Polymorphisms
or other genomic features may exist in these individuals who
do not exert changes in the transcriptome until the tumor is chal-
lenged with therapy. Alternatively, changes at the transcriptional
level may be too small to detect, especially when the signal orig-
inates from only a marginal population of cells within the tumor
(progenitor cells or a low penetrant colony). This suggests the
need for greater integration of physiologic, epidemiological,
and environment data into genomic studies and underscores
the need for tumor progression studies.
Lastly, the inherently difficult, poor-outcome individuals corre-
spond to patients for whom almost every classifier predicts
incorrectly as good outcome. One of the possible explanations
for the inherent difficulty is the existence of low-penetrant sub-
colonies or rare populations of atypical progenitor cells capable
of forming resistance to standard of care. Likely undetectable in
bulk profiling, these classifiers would not be able to differentiate
such tumors. If tumor heterogeneity is the primary cause of resis-
tance to therapy and subsequent poor outcome, it is these indi-
viduals who aremost likely to harbor the intratumoral complexity.
A preliminary study examining a series of ER/HER2 tumors
from patients determined as easy good, difficult good, and diffi-
cult bad prognosis by exomic deep sequencing (400–600
average depth) suggests that the chromosomal aberrations of
the inherently difficult poor-outcome sample is structurally
most similar to the inherently easy, good-outcome sample. At
least in this pilot study, the inherent complexity of patients is
conserved at the DNA level, although all three tumors harbor
both distinct and shared mutations.Conclusions
Given the limited nature of genomic studies in breast cancer to
date, no prognostic classifier should achieve a perfect success
rate at time of diagnosis, since this would imply that lifestyle, ex-
posures, tumor heterogeneity, and genotype do not play a role in
determining disease course. Our findings suggest that markers
of patient outcome at time of diagnosis exist, although they are
subtype specific, relatively rare, and imperfect.
We identified 20% of IBCs whose prognosis appears inher-
ently difficult to predict, with approximately one-third of these
patients of poor outcome. This latter cohort should be the priority
for studies via massively deep sequencing, since it is only these
patients who likely harbor clinically relevant intratumoral hetero-
geneity affecting disease progression.
Our approach and website provide the community with a
resource to cross-compare findings in the continual stream of
new data sets, subtyping schemes, and signatures for breast
cancer. This will make more precise the true nature of a pro-
posed biomarker after detangling the effects of confounding
factors, a problem that has plagued breast cancer informatics
to date.EXPERIMENTAL PROCEDURES
Expression Data
We compiled publicly available gene expression profiles of IBC (n =10K) and
evaluated each data set according to criteria including quality and technical
disparities of the microarray/sequencing technology, availability of clinical and
histopathological information, nonoverlap of patients, and overall size. We
harmonized as much as possible differences in follow-up time and defined
poor outcome as an observed distant metastasis within 5 years of diagnosis
(Supplemental Experimental Procedures, 2.1). The procedure produced a
compendium of 4,952 patients (ExpC) with expression measured with seven
distinct technologies including several microarray and RNA-seq platforms
(Table S1). Approval for the de novo MGGQ dataset was received from the
McGill ethical review board (#A10-M92-10A).
Subtyping Schemes
We used ER status as measured by IHC reported and HER2 status measured
by fluorescence in situ hybridization or immunohistochemistry where avail-
able. When unavailable, HER2 status was determined using gene expression
ofmembers of the HER2 amplicon as previously done (Staaf et al., 2010). Since
many of the data sets lacked information on the PR status, we used only ER
and HER2 status either in isolation or in combination to define eight possible
cohorts (ER+, ER, HER2+, HER2, and the four clinical subtypes using
ER/HER2). All ExpC samples were labeled according to four additional subtyp-
ing schemes from the literature: IntClusters (Curtis et al., 2012), CIT (Guedj
et al., 2012), TNBC (Lehmann et al., 2011), and intrinsic subtypes via PAM50
(Parker et al., 2009) (Figure 1A; Table S7).
Previously Reported Prognostic Signatures
Our goal was a systematic cross-comparison of all signatures (sets of genes)
reported to have prognostic capacity for IBC in the literature. In total, the signa-
ture collection (SigC) contains n = 106 gene sets ranging in size from three to
886 (Table S3).
Construction of Prognostic Classifiers
A unique classifier was built for each signature in SigCwithin each stratification
defined by clinical variables (e.g., ER+, HER2) and intrinsic subtypes (lumA,
lumB, normL, her2E, and basalL). Combinations of the clinical and intrinsic
subtyping schemes (e.g., ER+/basalL) were also considered. The naive Bayes’
classifier (NBC) was trained under leave-one-out cross-validation (1) for each
signature, (2) for each patient cohort, and (3) within each individual data set of
the ExpC, for which there were sufficient numbers of event (distant metastasis
within 5 years; poor-outcome) and event-free (good-outcome) individuals (Fig-
ure 1A; Supplemental Experimental Procedures, 2.7). NBCs were chosen as
they provide a simple, transparent, and uniform technique to cross-evaluate
the signatures, although some signatures were originally developed using
other techniques (detailed in Table S3). In addition to the gene signatures of
the SigC, the prognostic capacity of clinical attributes including grade, stage,
LN status, and age were considered. A small number of signatures in SigC
have been further developed into tools to aid during treatment decisionmaking
(e.g., Oncotype DX and MammaPrint). Here, we classify patients according
to the output from NBCs and not according to the methods of those tools.
Lastly, the prognostic capacity of each gene was evaluated across each
data set of the ExpC with respect to every possible subtype (Supplemental
Experimental Procedures, 2.2 and 2.9).
Construction of De Novo Prognostic Classifiers per Subtype
In addition to existing prognostic signatures, we also constructed de novo
prognostic signatures for each subtype (Figure S2). For some subtypes, such
as the hybrid ER+/basalL, these represent the only available classifiers. To-
ward this end, the ExpC was tripartitioned into learning (n = 897; van Vliet
et al., 2008), training (n = 819), and validation (n = 2,412) data sets (Tables S1
and S7). The training and validation data sets were chosen so that each
underlying technology (microarray or sequencing platform) was present. Using
the learning data set, our approach samples a set of k genes from the n most
prognostic genes in univariate analysis (absolute value of Cox-PH coefficient).
This sampling is repeated m times and each such sample is used to construct
an NBC in each data set of the learning partition. We experimented with
parameterizations of this approach and found that k = 25, n = 100, and
m = 25K provided small but high-performing classifiers (Figure S2F). Only the
classifier that achieves the maximum observed performance across the m =
25K samples in the learning and training data sets is tested in the validationdata set. This procedure is repeated for each of the target subtypes. A wide
range of measures were used to evaluate performance on the validation data
sets including the log-rank test, Cox proportional hazard, area under the curve,
Matthews correlation coefficient, Fisher’s exact test, and de novo permutation
tests (Supplemental Experimental Procedures, 2.7; Figures S2G and S2H).
Further analyses are available at http://www.bci.mcgill.ca/bresect.
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